Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Biodexa Pharmaceuticals ( (BDRX) ) is now available.
On January 5, 2026, Biodexa Pharmaceuticals announced the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary and her election to the company’s Board of Directors, effective immediately. Sharp, who joined Biodexa as Group Financial Controller in December 2019, brings extensive senior finance experience from the UK healthcare and communications sectors, including prior roles at Hywel Dda University Health Board and Chime Communications Group. As part of the leadership reshuffle, Stephen Stamp relinquishes his CFO and Company Secretary roles but remains Chief Executive Officer, a move that reinforces Biodexa’s governance structure and clarifies executive responsibilities as the company advances its clinical pipeline.
The most recent analyst rating on (BDRX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
The score is pressured primarily by weak financial performance (zero 2024 revenue, persistent losses, and significant ongoing cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation does not provide a clear offset due to negative earnings and no dividend yield data.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a Cardiff, UK‑based, clinical-stage biopharmaceutical company listed on Nasdaq under the ticker BDRX. It is developing a pipeline of innovative therapies targeting diseases with unmet medical needs, led by eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare or orphan brain cancers, supported by three proprietary drug delivery technologies designed to improve bio‑delivery and bio‑distribution of medicines.
Average Trading Volume: 1,108,551
Technical Sentiment Signal: Sell
Current Market Cap: $1.52M
For a thorough assessment of BDRX stock, go to TipRanks’ Stock Analysis page.